Date: March, 25<sup>™</sup>, 2021 Your Name: Trystram Noémie

Manuscript Title: Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab

treatment for metastatic melanoma: a case report Manuscript number (if known): APM-21-58-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
_	educational events	V Maga
6	Payment for expert testimony	_X_None
	testimony	
-	C	V N
7	Support for attending meetings and/or travel	_X_None
8	Patents planned, issued or	_X_None
	pending	
9	Participation on a Data	_X_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_X_None
12	Receipt of equipment,	_X_None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	_X_None
	financial interests	
		·

None		

Please place an "X" next to the following statement to indicate your agreement:

Date: March, 29<sup>Th</sup>, 2021 Your Name: Laly Pauline

Manuscript Title: Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab

treatment for metastatic melanoma: a case report Manuscript number (if known): APM-21-58-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
_	educational events	V Maga
6	Payment for expert testimony	_X_None
	testimony	
-	C	V N
7	Support for attending meetings and/or travel	_X_None
8	Patents planned, issued or	_X_None
	pending	
9	Participation on a Data	_X_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_X_None
12	Receipt of equipment,	_X_None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	_X_None
	financial interests	
		·

None		

Please place an "X" next to the following statement to indicate your agreement:

Date: March, 29<sup>Th</sup>, 2021

Your Name: Bertheau Philippe

Manuscript Title: Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab

treatment for metastatic melanoma: a case report Manuscript number (if known): APM-21-58-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
_	educational events	V Maria
6	Payment for expert testimony	_X_None
	testimony	
-	C	V N
7	Support for attending meetings and/or travel	_X_None
8	Patents planned, issued or	_X_None
	pending	
9	Participation on a Data	_X_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_X_None
12	Receipt of equipment,	_X_None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	_X_None
	financial interests	
		·

None		

Please place an "X" next to the following statement to indicate your agreement:

Date: March, 29<sup>Th</sup>, 2021

Your Name: Baroudjian Barouyr

Manuscript Title: Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab

treatment for metastatic melanoma: a case report Manuscript number (if known): APM-21-58-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
_	educational events	V Maria
6	Payment for expert testimony	_X_None
	testimony	
-	C	V N
7	Support for attending meetings and/or travel	_X_None
8	Patents planned, issued or	_X_None
	pending	
9	Participation on a Data	_X_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_X_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_X_None
12	Receipt of equipment,	_X_None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	_X_None
	financial interests	
		·

None		

Please place an "X" next to the following statement to indicate your agreement:

Date: March, 25<sup>Th</sup>, 2021 Your Name: Aparicio Thomas

Manuscript Title: Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab

treatment for metastatic melanoma: a case report Manuscript number (if known): APM-21-58-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None		
Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None		
3	Royalties or licenses	_X_None		
4	Consulting fees	_X_None		

5	Payment or honoraria for lectures, presentations,	Presentations for MSD
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	_X_None
7	Support for attending meetings and/or travel	_X_None
8	Patents planned, issued or	_X_None
	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None
10	Leadership or fiduciary role	_X_None
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_None
13	Other financial or non- financial interests	_X_None

Presentations for MSD		

Please place an "X" next to the following statement to indicate your agreement:

Date: March, 27<sup>Th</sup>, 2021

Your Name: Gornet Jean-Marc

Manuscript Title: Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab

treatment for metastatic melanoma: a case report Manuscript number (if known): APM-21-58-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations,	_X_None
	speakers bureaus,	
	manuscript writing or	
_	educational events	V Maria
6	Payment for expert	_X_None
	testimony	
-	C	V N
7	Support for attending meetings and/or travel	_X_None
8	Patents planned, issued or	_X_None
	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None
10	Leadership or fiduciary role in other board, society, committee or advocacy	_X_None
	group, paid or unpaid	
11	Stock or stock options	_X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_None
13	Other financial or non- financial interests	_X_None
		·

None			

Please place an "X" next to the following statement to indicate your agreement: